Optimizing Pharmacovigilance And Risk Management Strategies To An Evolving Drug Safety Environment
As medical science advances, so does our understanding of drug safety and the need for vigilance when it comes to monitoring its usage. In recent years, pharmacovigilance has gained significant attention and importance due to the growing complexity of drug therapies, the emergence of new medicines, and the increased scrutiny of regulatory agencies. This has led to a greater emphasis on monitoring the safety profiles of pharmaceutical products throughout their lifecycle, from pre-marketing clinical trials to post-marketing surveillance.
The need for effective pharmacovigilance systems becomes even more crucial as the global population continues to expand, resulting in an increased consumption of medications. Adverse drug reactions (ADRs) can have severe consequences, leading to hospitalizations, prolonged treatments, and in some cases, even fatalities. Therefore, it is imperative to enhance our understanding of ADRs, identify potential risks, and implement appropriate risk mitigation strategies. To efficiently address these challenges, collaboration between international regulatory bodies, healthcare providers, and patients is essential. With a strong focus on patient safety as well as public health and by creating an interconnected network of experts from around the world who are dedicated to advancing our understanding of drug safety and pharmacovigilance, we can create a robust system.
This conference will serve as a knowledge-sharing and networking platform, providing a unique opportunity for researchers, pharmacists, healthcare professionals, industry representatives, and regulatory authorities to come together and discuss the latest trends, challenges, and advancements in pharmacovigilance. By sharing experiences and best practices, we aim to enhance global drug safety and improve patient outcomes. Throughout the conference, we will delve into various topics such as signal detection and management, adverse event reporting and analysis, risk assessment, benefit-risk evaluation, regulatory updates, collaboration and the integration of artificial intelligence and digital technologies in pharmacovigilance.
Our esteemed panel of speakers, comprising leading experts from academia, industry, and regulatory agencies, will present their research findings, share case studies, and engage in thought-provoking discussions. The conference will also feature interactive networking opportunities, fostering collaboration and enabling the exchange of ideas.
We are delighted to welcome you to the Pharmacovigilance World 2025, and we are confident that your active participation will contribute to the advancement of drug safety practices. Together, let us strive towards a safer and more vigilant healthcare system that prioritizes patient well-being and ensures the continued benefit of medications worldwide.
Conference Streams Include
- Global PV & Methodologies
- Data Management & Analytics in PV
- PV Automation, AI & Machine Learning
- Safety Signals & Management
- Pharmacovigilance Regulations
- Risk Management
- Patient-Centric Drug Safety
- Case Management
- Quality & Compliance
- Pharmacovigilance Outsourcing
- Medical Devices Safety
- Adverse Drug Reactions
Key Discussions We'll Be Exploring
- Pharmacovigilance and globalization
- Pharmacovigilance in a pandemic world
- Women and child healthcare medicines and pharmacovigilance
- Patient-centric approaches in PV
- Pharmacovigilance legislation and regulations
- Harmonization and pharmacovigilance
- Advanced therapeutic techniques and pharmacovigilance
- Pharmacovigilance and data management and eudravigilance
- Post-marketing surveillance in pharmacovigilance
- PV regulations and challenges
- Benefit-risk management strategies
- Risk management and minimization
- Risk Evaluation and Mitigation
- Adverse drug reaction reporting
- Signal detection and post-authorization safety
- Good Pharmacovigilance Practices
- Innovative approaches to drug safety
- Strategies to improve PV
- Real-World Evidence in PV
- Big data and AI in pharmacovigilance
- Pharmacovigilance Workflows with AI & Automation
- Other emerging technologies in PV
Who Should Attend
C-level, Presidents, Senior/Global Vice Presidents, Directors, Directors, Heads & Managers, Scientific Advisors, Consultants and professionals who work for pharmaceutical, biotechnology & devices industries, CROs and service providers involved in Pharmacovigilance and Drug safety.
- Pharmacovigilance
- Safety & Risk management
- Drug safety
- PV Compliance
- Safety Surveillance
- Medical Affairs
- Regulatory Affairs
- Inspection and Audit
- Pharmacoepidemiology
- Post-market studies
- Medical product safety assessment
- Drug Research & Development
- Clinical Pharmacology
- Medical information
- Contract outsourcing service providers
- Health outcomes
- Sales and Marketing
Location
ADDRESS
London
United Kingdom
Venue to be announced shortly.
